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Abstract
Hepatocytes differentiated from induced pluripotent stem cells or stem cells have the potential to be representative in vitromodels
of the human liver for research as well as early safety assessment programs. However, up until now, there has been no definitive
proof that differentiated hepatocytes recapitulate the phenotype and functional characteristics of primary hepatocytes from the
same individual. Thus, a method for the concurrent isolation of hepatocytes and hepatic stem cells is presented here to provide the
cells necessary for the evaluation of the required benchmarking. The method presented here generated high-quality hepatocytes
with a purity of 94 ± 1% and a high percentage viability of 79 ± 2%. Furthermore, the hepatic stem cells isolated were found to be
actively proliferating and have a purity of 98 ± 1%. Thus, these isolated cells can be used as a powerful tool for the validation of
differentiated hepatocyte in vitro models.
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Introduction
The cost of bringing a new drug to market has skyrocketed
mainly due to the outlay on phase 2 and 3 trials and late-stage
failures (Orloff et al. 2009). Reducing late-stage drug attrition
costs can best be done by early safety assessment programs.
Currently, human primary hepatocytes are used as the “gold
standard” in vitro model in such programs. While this model
has many advantages, its usage also brings substantial chal-
lenges in a pharmaceutical environment. These challenges in-
clude limited quantity available, lack of availability when re-
quired, variable quality of hepatocytes dependent on the tissue
quality or isolation procedures, uncharacterised enzymatic pro-
files when cells are received and long waiting times for a spe-
cific donor profile. Thus, it is very important to establish an
equivalent in vitro human model without these disadvantages.
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The use of hepatocytes differentiated from induced plurip-
otent stem cells (iPSC) could be an ideal solution as such
hepatocytes could potentially provide unlimited in vitro
models with pre-characterised and desired phenotypic back-
grounds. Moreover, it offers the opportunity to include differ-
ent disease phenotypes in drug toxicity testing. However, de-
spite many attempts over the years to generate hepatocytes
from iPSCs (iPSC-Heps), no iPSC-Heps representative of do-
nor phenotype has been produced to our knowledge.
One of the reasons for this difficulty is obtaining a
mature and stably differentiated phenotype. Generating
iPSCs from Hepatic Stem Cells (HSCs) could help with
this problem. Hepatic stem cells in this text refer to self-
renewing cells that have the potential to give rise to both
hepatocytes and cholangiocytes (Schmelzer et al. 2007).
The actual nomenclature to be used, whether the term
HSC or hepatic progenitor cell is still unclear and contro-
versial in the literature. The reasons that we choose to
isolate HSCs in particular are manifold. Firstly, iPSCs
generated from bipotential HSCs could retain a transient
transcriptional memory that facilitates differentiation into
hepatocytes especially at lower passage numbers (Lee
et al. 2012). Secondly, unlike hepatocytes, HSCs can pro-
liferate in culture and this could promote the formation of
induced pluripotent stem cells (Panopoulos et al. 2012).
Thirdly, if reprogramming to iPSCs is not desired, hepa-
tocytes can be directly differentiated from HSCs, which
have been shown to be able to persist in culture for up to
100 passages over 2 yr (Wang et al. 2010). The ability to
keep HSCs in long-term culture will also allow investiga-
tors to examine differences due to reprogramming and the
inf luence of long- term cul ture with or without
reprogramming on subsequent differentiation to hepato-
cytes. Previously published works show that Epithelial
Cell Adhesion Molecule (EpCAM), a transmembrane gly-
coprotein, is an extracellular marker expressed by HSCs
(Schmelzer et al. 2007; Okabe et al. 2009) and this marker
will be targeted for the isolation of HSCs in this work.
The other major reason that has made it impossible to say if
differentiated hepatocytes have been successfully produced
was the lack of primary hepatocytes from the same donor
for benchmarking. Until today, almost all previous studies
have compared functional properties of differentiated hepato-
cytes, such as cytochrome P450 enzyme activities, against
other less relevant cell types such as undifferentiated iPSCs,
early stages of differentiating stem cells or hepatic cell lines
(Ulvestad et al. 2013). However, this strategy of comparing
against cell types with little or no mature hepatocyte charac-
teristics does not allow a conclusion that the donor phenotype
as seen in the primary hepatocytes has been recreated.
Therefore, this study aims to provide a powerful tool to
researchers to address these issues by providing a method to
isolate HSCs and hepatocytes from the same donor.
Materials and Methods
Isolation of hepatocytes and hepatic stem cells Pieces of mac-
roscopically normal liver with 1 sectioned surface from do-
nors undergoing elective surgeries for secondary metastasis to
the liver were included in this study. The liver samples were
provided double-coded by the Biobank under the administra-
tion of the Human Tissue and Cell Research (HTCR)
Foundation at the Ludwig-Maximilians-University (LMU).
The framework of the HTCR Foundation, which includes
written informed consent from all donors, has been approved
by the ethics commission of the Faculty of Medicine in the
LMU (number 025-12) and the Bavarian State Medical
Association (number 11142).
A modified (Lee et al. 2013) two-step collagenase perfu-
sion technique (Lee et al. 2013; Berry and Friend 1969;
Seglen 1973) was used to prepare a cell suspension containing
human hepatocytes and HSCs. In brief, irrigation cannulas
with olive tips were inserted snugly into the larger blood ves-
sels on the cut face of the piece of the liver for perfusion at
37°C. The liver was perfused sequentially with perfusion buff-
er (154 mM sodium chloride, 20 mM HEPES, 5.6 mM potas-
sium chloride, 5 mM glucose and 25 mM sodium hydrogen
carbonate), perfusion buffer containing 1 mM EGTA, perfu-
sion buffer containing 5 mM calcium chloride dihydrate and
finally perfusion buffer containing 5 mM calcium chloride
dihydrate and 250 to 400 U ml−1 collagenase (Nordmark
Biochemicals, Uetersen, Germany). Enzymatic digestion with
collagenase was carried out in a recirculating manner for 9 to
12min or until the liver is sufficiently digested. The liver piece
was then placed carefully in a crystallising dish for removal of
the Glisson’s capsule before gently shaking the cells loose.
The cell suspension was then filtered through a 210-μm nylon
mesh followed by a 70-μm nylon mesh.
After filtration, the cell suspension was centrifuged at 72g
for 5 min at 4°C. The first supernatant obtained, which
contained the HSCs, was transferred to new centrifuge tubes
and set on ice for the subsequent isolation of HSCs. The he-
patocyte pellet was resuspended in wash buffer (120 mM so-
dium chloride, 10 mM HEPES, 0.9 mM calcium chloride
dihydrate, 6.2 mM potassium chloride and 0.1%w/v albumin)
for hepatocyte isolation.
To complete hepatocyte isolation, the hepatocytes were
washed by centrifugation at 72g for 5 min at 4°C followed
by aspirating off the wash buffer in the supernatant and
topping up the centrifuge tube with fresh wash buffer. The
above washing step was repeated twice. On the last centrifu-
gation step, the hepatocytes were resuspended in the appro-
priate cell culture media for a haemocytometer-based trypan
blue exclusion assay to determine hepatocyte yield and viabil-
ity. At this stage, the purified hepatocytes can be used in sus-
pension or adhered to collagen-coated plates for further exper-
iments. For adherence to 6-well Biocoat™ collagen 1-coated
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plates (Corning, Corning, NY), 1.2 million hepatocytes in
hepatocyte cell culture media were added per well. These
hepatocytes were allowed to adhere for 4 h in an incubator
at 37°C. Thereafter, a media change was carried out to remove
any non-adhered cells. The hepatocyte culture medium used
was DMEM media supplemented with 800 μg/l hydrocorti-
sone, 125 U/l insulin, 100 U/ml penicillin, 100 μg/ml strepto-
mycin, 2 mM L-glutamine, 7.4 μg/l glucagon and 10% FCS.
To complete HSC isolation from the supernatant generated
by the first centrifugation, the remaining contaminating hepa-
tocytes had to be removed. This was done by centrifuging at
100g for 5 min at 4°C and transferring the supernatant to new
centrifuge tubes at least twice or until no hepatocyte pellet can
be seen after centrifugation. The supernatant free of hepato-
cytes was then centrifuged at 300g for 5 min at 4°C to obtain a
non-parenchymal cell pellet containing HSCs. The cell pellet
was resuspended in a volume of degassed cell suspension
buffer (Phosphate Buffered Saline (PBS) containing 2 mM
Ethylenediaminetetraacetic Acid (EDTA) and 0.5% w/v
Bovine Serum Albumin (BSA)) at least equal to the volume
of the pellet before carrying out red blood cell lysis using a kit
from Miltenyi Biotec (Teterow, Germany) according to the
manufacturer’s instructions. After red blood cell lysis, the cells
were resuspended in cell suspension buffer and centrifuged at
300g for 5 min at 4°C. After resuspension in a small volume of
cell suspension buffer, the cell suspension was filtered through
a 70-μm cell strainer (Miltenyi Biotec) and counted using a
haemocytometer.
Next, magnetic-activated cell sorting (MACS) was car-
ried out to positively select Epithelial Cell Adhesion
Molecule (EpCAM)-expressing HSCs. There have been
many markers used for HSC isolation in a variety of spe-
cies. For this article, EpCAM was chosen as it has been
shown to be consistently expressed in normal liver tissue
(Schmelzer et al. 2007; Okabe et al. 2009). Briefly, cells
were resuspended to a concentration of 50 million total
cells per 0.3 ml of cell suspension buffer before adding
0.1 ml of FcR Blocking reagent (Miltenyi Biotec) follow-
ed by 0.1 ml of EpCAM microbeads (Miltenyi Biotec) for
each 50 million portion of cells. After swirling the cell
suspension, the mixture was incubated at 4 to 8°C for
30 min. After the incubation period, cells were washed
in cell suspension buffer and resuspended with up to
200 million cells ml−1 cell suspension buffer before car-
rying out magnetic selection. Magnetic selection was car-
ried out using the MiniMACS™ Separator with MS
Columns (Miltenyi Biotec) according to the manufac-
turer’s instructions.
After magnetic selection, the purified HSC suspension was
centrifuged at 300g for 5 min at 4°C. The pellet was resus-
pended in oval cell culture medium (William’s Medium E
containing 10% FCS, 10 mM nicotinamide, 2 mM L-gluta-
mine, 0.2 mM ascorbic acid, 20 mM HEPES, 1 mM sodium
pyruvate, 17.6 mM sodium bicarbonate, 14 mMα-D-glucose,
100 nM dexamethasone, 1X Insulin-Transferrin-Selenium,
0.5 μg ml−1 gentamicin, 10 ng ml−1 recombinant human epi-
dermal growth factor, 10 ng ml−1 recombinant human hepa-
tocyte growth factor and 10 ngml−1 interleukin 6) and adhered
on Corning™ Biocoat™ collagen 1-coated plates for further
experiments (Okabe et al. 2009).
Immunofluorescent staining Ten-micrometer cryosections on
microscope slides (Marienfeld-Superior, Lauda-Königshofen,
Germany) or cells adhered on 8-well culture slides coatedwith
collagen were stained using immunofluorescence. In brief, the
specimens were fixed for 10 min in 10% neutral-buffered
formalin and subsequently permeabilised using 0.5% triton
in PBS. After blocking with PBS containing 10% goat serum
and 0.1% triton for a minimum of 1 h at room temperature,
specimens were incubated with primary antibodies at 4°C
overnight. Primary antibodies used were against Cytokeratin
19 (CK19) (PA5-29582, Thermo Fisher Scientific, Waltham,
MA), albumin (PA5-27707, Thermo Fisher Scientific) and Ki-
67 (ab15580, Abcam, Cambridge, UK). The primary antibod-
ies were used at a dilution of 1:100, 1:100 and 0.5 μg antibody
ml−1 respectively. The next day, the specimens were incubated
with the secondary antibodies conjugated with Alexa Fluor
488 (A-11034, Thermo Fisher Scientific) and 594 (A-11020,
Thermo Fisher Scientific) for 1.5 h. The 2 secondary antibod-
ies were used at a dilution of 1:500. Finally, cover slips were
mounted using Prolong Gold Antifade Mountant (Thermo
Fisher Scientific).
CYP1A2 activity measurement CYP1A2 activity was deter-
mined using the P450-Glo CYP1A2 luminescent assay kit
(Promega Corporation, San Luis Obispo, CA) according to
the manufacturer’s instructions.
Fluorescence-activated cell sorting To prepare cells for analy-
sis, cells were fixed with 10% neutral-buffered formalin for
10 min at 37°C followed by chilling on ice for 1 min. Next,
cells were permeabilised by the slow addition of ice-cold
100% methanol to a final concentration of 90% methanol
before incubation on ice for 30 min. Cells were then blocked
in PBS containing 0.5% BSA for 10 min at room temperature.
Incubation of the cells with the primary anti-albumin antibody
(PA5-27707, Thermo Fisher Scientific) at 5 μg antibody ml−1
was done for 1 h followed by 30-min incubation with a sec-
ondary antibody conjugated to Alexa Fluor 488 (A-11034,
Thermo Fisher Scientific) at 5 μg antibody ml−1. Washing
with PBS containing 0.5% BSA was carried out in between
the key steps mentioned above.
Fluorescence-activated cell sorting (FACS) was carried out
using a FACSCalibur (BD Biosciences, Heidelberg,
Germany) and data collected was analysed using FlowJo ver-
sion 10 (Flowjo LLC, Ashland, OR).
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Statistical analysis Values are presented as means ± standard
error of the mean. Two-tailed paired t tests done using Spss
Statistics (IBM, Armonk, NY) were used to identify signifi-
cant differences (P < 0.05) between means.
Results
CK19+ cells express EpCAM in human normal and cirrhotic liver
In order to validate the usage of EpCAM+ as a selection mark-
er for human HSCs in our laboratory, expression was exam-
ined in human normal and cirrhotic liver cryosections (Fig. 1).
Similar to the DDC-fed mice, an increase in ductular struc-
tures formed by EpCAM+ cells was seen in human cirrhotic
liver (Fig. 1a). All these EpCAM+ cells also expressed
Cytokeratin 19 (CK19 (Fig. 1b)), a marker of HSCs and
cholangiocytes. This marker expression pattern was also seen
in normal liver, albeit with markedly less ductular structures
present when compared with the cirrhotic liver (Fig. 1d–f).
Thus, similar to the mouse model, all human HSCs that ex-
press CK19 also expressed EpCAM (Fig. 1c, f), meaning that
EpCAM can be used as the selection marker.
Characterisation of isolated hepatocytes Characterisation of
hepatocytes isolated in parallel with HSCs shows that the
isolated hepatocytes had a high average viability of 79 ± 2%
with a yield of 5 ± 1 million hepatocytes per gram liver (N =
11). Furthermore, phase contrast microscopy showed that the
isolated hepatocytes exhibited key characteristics of hepato-
cytes; isolated cells were large polygonal cells with numerous
binucleate cells (Fig. 2a). In addition, immunofluorescent
staining showed that these isolated cells expressed hepatocyte
marker albumin (Fig. 2b). Finally, these cells expressed a bas-
al activity of CYP1A2 (0.31 ± 0.08 nmol luciferin mg−1 pro-
tein), which could be induced after treatment with 100 μM of
omeprazole to 2.48 ± 0.37 nmol luciferin mg−1 protein for 2 d
(Fig. 2d). Thus, hepatocytes isolated using this method are
suitable for further experiments.
Characterisation of isolated hepatic stem cells This isolation
method yielded 1.2 ± 0.2 million live non-parenchymal cells
per gram liver (N = 12) for the subsequent isolation of
EpCAM+ cells. After carrying out MACS, the yield of posi-
tively selected EpCAM+ cells was 15,076 ± 4307 cells per
gram liver (N = 12). Since relatively large pieces of liver were
Figure 1. EpCAM and CK19
colocalise in human liver.
Immunofluorescent staining of
EpCAM and CK19 in cirrhotic
(a–c) or in macroscopically
normal liver (d–f). EpCAM
localisation is visualised in red in
panels (a) and (d), while CK19
localisation is visualised in green
in panels (b) and (e). Co-localised
expression of EpCAM and CK19
can be seen in panel (c) for cir-
rhotic liver and panel ( f ) for
normal liver. Scale bars in the
figure indicate a length 100 μm.
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used for cell isolation, the total yield of 0.86 ± 0.21 million
EpCAM+ cells was sufficient for further experiments.
Immediately after isolation, EpCAM+ cells were




image of hepatocytes adhered to
collagen 1-coated plate 2 d after
isolation. (b) Representative im-
munofluorescent image showing
characteristic albumin (green)
staining in hepatocytes with (c)
corresponding secondary anti-
body control image. Nuclei were
counterstained blue using DAPI.
(d) CYP1A2 activity was induced
in hepatocytes after treatment
with 100 μM omeprazole for
48 h. Values from 3 biological
replicates are presented in the
histogram. *Significantly differ-
ent from control, P < 0.05. Scale
bars in the figure indicate a length
100 μm.
Figure 3. Characterisation of
EpCAM+ cells immediately after
isolation. (a) Representative
pseudocolor plot showing the
forward and side scatter of the
isolated EpCAM+ cells. (b)
Overlaid histograms showing
control/unstained cells (filled
black) and albumin+ cells (dotted
line). Ninety-eight percent of the
isolated EpCAM+ cells expressed
albumin, a marker expressed by
hepatic stem cells. (c)
Representative phase contrast im-
age of hepatic stem cells 1 d after
isolation showing characteristic
oval nuclei and scant cytoplasm.
The scale bar in the figure indi-
cates a length 100 μm.
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scatter of the population of EpCAM+ cells. When examined for
albumin expression, 98 ± 1% of the cells were found to express
this marker (Fig. 3b). Since we have established that EpCAM+
cells also express CK19, the co-expression of CK19 and albu-
min indicates that the isolated cells are a pure population of
HSCs. Phase contrast images taken 1 d after isolation support
this assertion as it can be seen that the isolated cells have ovoid
nuclei and scant cytoplasm characteristic of HSCs (Fig. 3c).
Furthermore, cultured cells maintained stem cell phenotype
on day 5 of culture as evidenced by the co-expression of albu-
min (Fig. 4a) and CK19 (Fig. 4b) in Fig. 4c. In addition, all of
these cells expressed Ki67 (Fig. 4e), a marker of proliferation.
Cell proliferation is of note as it could promote the formation of
iPSCs (Panopoulos et al. 2012), which is a common goal for
many researchers who work with HSCs.
Discussion
Okabe et al. (Okabe et al. 2009) published a simple FACS-
based method for the isolation of mouse HSCs through the
selection of EpCAM+ cells in normal and injured liver. Their
publication reported that the yield of HSCs from mouse livers
injured by a 3,5-diethoxycarbonyl-1,4-dihydro-collidine
(DDC)-containing diet was more than 2-fold compared with
normal livers (Okabe et al. 2009). DDC is a porphyrinogenic
agent that causes chronic oxidative liver damage, hepatocyte
ballooning and the formation of Mallory-Denk bodies (De
Matteis et al. 1973; Snider et al. 2011). Further evidence that
EpCAM is a suitable isolation marker comes from Schmelzer
et al. (Schmelzer et al. 2007), who have used EpCAM selec-
tion to isolate HSCs from neonatal, pediatric and adult livers
with the finding that neonatal and pediatric livers yield 2- to 3-
fold more EpCAM+ cells. Although a lower HSC yield from
normal livers has been reported by the above authors
(Schmelzer et al. 2007; Okabe et al. 2009), we believe that it
is important to optimise and present a method to isolate HSCs
and hepatocytes from normal human livers using EpCAM
marker selection. One of the reasons for this importance is
that although many authors have generated iPSCs from der-
mal fibroblasts and peripheral blood cells with subsequent
differentiation to hepatocytes, these studies either did not
compare the iPSC-Heps to primary human hepatocytes or
were not able to compare the iPSC-Heps to primary
Figure 4. Hepatic stem cell
characterisation.
Immunofluorescent labelling of
(a) albumin (green) and (b) CK19
(red) in hepatic stem cells 5 d after
isolation with the co-localised
expression of albumin and CK19
shown in panel (c). The corre-
sponding secondary antibody
control image is shown in panel
(d). These cells express (e) pro-
liferation marker Ki67 (green) in
the nuclei making them appear
cyan when compared with the
corresponding ( f ) secondary an-
tibody control with blue nuclei.
Nuclei are counterstained blue
with DAPI. Scale bars in the fig-
ure indicate a length 100 μm.
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hepatocytes from the same donor (Ghodsizadeh et al. 2010;
Kajiwara et al. 2012; Krueger et al. 2013; Ulvestad et al.
2013). With the aim of isolating HSCs and primary hepato-
cytes from the same liver, this method can provide a powerful
tool to determine if hepatocytes derived from HSCs or iPSCs
generated from HSCs can reproduce the key characteristics of
hepatocytes from the same donor. If desired, iPSC-Heps de-
rived from peripheral blood cells of the same donor can also
be tested as it is generally possible to obtain a small volume of
blood with written informed consent. This will allow re-
searchers to identify the effects due to reprogramming to
iPSCs and to understand the influence of different starting cell
types for reprogramming. Another reason to publish this
method is that although there are methods available to isolate
HSCs, to our knowledge, there is no detailed protocol avail-
able for the isolation of high-quality HSCs and hepatocytes
from the same donor.
Conclusions
In conclusion, a method for the concurrent isolation of hepa-
tocytes and HSCs has been successfully established. The
method presented here is relatively fast as no additional enzy-
matic digestion steps have been added after the 2-step colla-
genase perfusion of the liver piece was complete. This brings
the isolation time required down to a manageable time of
approximately 6 h as livers donated from elective surgeries
are usually received between early to late afternoon due to the
time needed for the operations.
The isolation of HSCs and hepatocytes from the same do-
nor will allow for the first time benchmarking of differentiated
hepatocytes to the isolated hepatocytes from the same donor.
In addition, when reprogramming to iPSC is undesirable,
HSCs can also be maintained in culture for a prolonged period
(Wang et al. 2010) for differentiation to hepatocytes.
Furthermore, the effects of reprogramming to iPSCs can also
be compared using HSCs due to their amenability to culture
and subsequent direct differentiation to hepatocytes.
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